🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522741-21-00
Completed Phase IV

Heart rate control: Betablockers or Ivabradine therapy before cardiac computed tomography

2025-522741-21-00 · tracked via the Priya Life Science EU tracker
Sponsor
Region Midtjylland
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Cardiovascular Diseases
Decision date
01/10/2025
Enrollment target
350
Sites
Denmark

Condition studied

ischemic heart disease

Investigational medicinal product(s)

IVABRADINEATENOLOLMETOPROLOL

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

The primary end point measure is the time to a heart rate (mean) lowered by 10% from baseline after adminstration of study drug

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522741-21-00 on CTIS ↗ ← All trials in the EU